Search - tctmd.com

Displaying 361 - 380 of 1055

Sort: Relevancy | Date

News Daily News

On the Frontier of CTO PCI for STEMI Patients: Answers Lead to More Questions in EXPLORE

Yael L. Maxwell

October 05, 2016

News Daily News

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Caitlin E. Cox

October 04, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

In Print at Last, Early Cardioband Results Show Safety, Feasibility at 6 Months

Shelley Wood

October 04, 2016

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2016

Shelley Wood

September 30, 2016

News Daily News

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

Shelley Wood

September 29, 2016

News Daily News

Post-TAVR Cognition Improves in Some Patients and Declines in Others, With Few Signposts to Guide the Way

Shelley Wood

September 29, 2016

News Daily News

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Shelley Wood

September 29, 2016

News Daily News

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Yael L. Maxwell

September 26, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

大型登记表显示 TAVR 后感染性心内膜炎后与糖尿病，残余主动脉瓣关闭不全相关

Yael L. Maxwell

September 14, 2016

News Daily News

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

Yael L. Maxwell

September 14, 2016

News Daily News

TAVR 伴随中风风险：PARTNER 研究深入审查和 CoreValve 数据揭示了机遇和未知

Shelley Wood

September 13, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

FDA Expands Indications for Two Endovascular Stroke Therapies

Todd Neale

September 06, 2016

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

Michael O'Riordan

August 18, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

Advertisement

On the Frontier of CTO PCI for STEMI Patients: Answers Lead to More Questions in EXPLORE

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

In Print at Last, Early Cardioband Results Show Safety, Feasibility at 6 Months

TCTMD’s Top 10 Most Popular Stories for September 2016

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

Post-TAVR Cognition Improves in Some Patients and Declines in Others, With Few Signposts to Guide the Way

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Amid Sparse Data on Infection After ASD Closure, Experts Urge Focus on Dental Health

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

大型登记表显示 TAVR 后感染性心内膜炎后与糖尿病，残余主动脉瓣关闭不全相关

La Endocarditis Infecciosa Post-TAVR se asocia a Diabetes, Regurgitación Aórtica Residual en un Extenso Registro

TAVR 伴随中风风险：PARTNER 研究深入审查和 CoreValve 数据揭示了机遇和未知

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

FDA Expands Indications for Two Endovascular Stroke Therapies

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

Medtronic Warns of Vascular Trauma, Some Resulting in Death, With CoreValve’s EnVeo R Delivery Catheter

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content